Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NQT4

UPID:
EXOS5_HUMAN

ALTERNATIVE NAMES:
Chronic myelogenous leukemia tumor antigen 28; Exosome component 5; Ribosomal RNA-processing protein 46; p12B

ALTERNATIVE UPACC:
Q9NQT4; Q32Q81; Q8NG16; Q96I89

BACKGROUND:
The protein Exosome complex component RRP46, known alternatively as Ribosomal RNA-processing protein 46, is integral to the RNA exosome complex. This complex is pivotal for the 3'->5' exoribonuclease activity, participating in cellular RNA processing and degradation events. RRP46 is involved in the maturation of rRNA, snRNA, and snoRNA, and the degradation of mRNAs with processing defects, playing a key role in RNA surveillance pathways.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in RNA processing and its association with cerebellar ataxia, brain abnormalities, and cardiac conduction defects, Exosome complex component RRP46 presents a promising target for drug discovery. Exploring the therapeutic potential of targeting RRP46 could lead to novel treatments for these complex disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.